{"schema_version":"1.0","type":"article","title":"Why Has Japan Struggled to Build Global-Scale Biotech Companies?","url":"https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.md","lang":"en","date":"2026-07-09","publish_at":"2026-07-09T09:30:00+08:00","updated_at":"2026-07-09","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Japan biotech","Taiwan biotech","startup ecosystem","drug development","clinical data","CMC","BD licensing","biotech valuation","capital markets","big pharma"],"summary":"Japan has strong science, major pharmaceutical companies, and a large drug market. The harder question is why that foundation has not produced more global-scale biotech startups. The answer is not scientific weakness, but an ecosystem gap across assets, talent, capital, clinical execution, and exits.","key_points":[],"facts":[],"sections":["01｜Japan Does Not Lack Innovation Foundations. It Lacks the Bridge From Science to Company Formation.","02｜When Big Pharma Is Too Dominant, Biotech May Lose Its Growth Space","03｜The Talent Problem Is Deeper Than It Looks","04｜Capital Depth Is the Most Practical Bottleneck","05｜Policy Reform Has Started, but Ecosystems Do Not Mature Overnight","06｜Why This Matters for Taiwan Investors","07｜Conclusion: Biotech Needs an Ecosystem Patient Enough to Let Companies Grow"],"references":[{"title":"Cabinet Secretariat, Government of Japan, [Startup Development Five-year Plan](), 2022.","source":"","date":"","url":"https://www.cas.go.jp/jp/seisaku/atarashii_sihonsyugi/pdf/sdfyplan2022en.pdf"},{"title":"Nature Index, [Japan country outputs]().","source":"","date":"","url":"https://www.nature.com/nature-index/country-outputs/Japan"},{"title":"Japan Agency for Medical Research and Development, [AMED official website]().","source":"","date":"","url":"https://www.amed.go.jp/en/"},{"title":"U.S. Food and Drug Administration, [Drug Trials Snapshot: Enhertu](), 2019.","source":"","date":"","url":"https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-enhertu"}],"images":[{"alt":"Figure 1 | Japan's biotech paradox: strong science, major pharma, large market, but few global biotech startups","url":"https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap-en/figure-01.png"},{"alt":"Figure 2 | Large pharma can become the main container for innovation, leaving the startup learning curve thin","url":"https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap-en/figure-02.png"},{"alt":"Figure 3 | Startup scaling needs talent mobility and risk capital across clinical, CMC, regulatory, and BD execution","url":"https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap-en/figure-03.png"},{"alt":"Figure 4 | Taiwan investors should read ecosystem position rather than chasing biotech themes","url":"https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-09）。Why Has Japan Struggled to Build Global-Scale Biotech Companies?。https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-09-japan-biotech-ecosystem-global-gap.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}